# Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

> **NCT02079246** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 1463 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Idalopirdine 60 mg

## Key facts

- **NCT ID:** NCT02079246
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-07
- **Primary completion:** 2017-07-06
- **Final completion:** 2017-07-06
- **Target enrollment:** 1463 (ACTUAL)
- **Last updated:** 2018-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079246, "Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02079246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*